CClinicalTrials.gg
CompletedNCT02213302Updated Feb 11, 2016

Premedication by Midazolam for Emergency Surgery

A Phase 4 interventional study of placebo administration and midazolam intravenous administration in Anxiety, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2016-02-11.

Sponsored by University Hospital, Lille · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

Preoperative anxiety is a subjective and painful experience and may have adverse psychological consequences and complicate anesthetic management. The aim of the study is to show the effect of premedication by midazolam on preoperative anxiety assessed by a visual analog scale and by measuring salivary cortisol levels. This study was a monocentric, prospective, blind randomized placebo controlled clinical study. Sixty patients, aged 18 to 79 years, to undergo elective surgery under general anesthesia with tracheal intubation must be enrolled and randomized to receive midazolam (0.02mg/kg) or placebo. The primary outcome is the reduction in anxiety assessed by a visual analog scale. The secondary outcomes are the reduction in salivary cortisol levels, the overall level of anxiety and the evaluation of respiratory and hemodynamic adverse effects of midazolam.

02

Conditions studied

  • Anxiety

Browse trials for

Keywords

  • premedication
  • preoperative anxiety
  • salivary cortisol level
  • anxiety visual analog scale
03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 59 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • major patient undergoing elective surgery under general anesthesia with tracheal intubation
  • Anesthesia state 1 and 2
  • preoperative fasting for 6 hours
  • information and signed consent
  • social security
  • non pregnant women

Exclusion criteria

Exclusion Criteria:

  • anesthesia state above 3
  • midazolam sensibility
  • pregnant or breastfeeding women
  • ICU patients
  • no consent
  • pediatric surgery
  • no social security
  • no tracheal intubation
  • required premedication in placebo group or midazolam sensibility in premedication group
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Placebo comparator
    Isotonic serum

    placebo administration

    Drug: placebo administration · Drug: midazolam intravenous administration

  • Active comparator
    Midazolam

    midazolam intravenous administration 0.02mg/kg

    Drug: placebo administration · Drug: midazolam intravenous administration

Interventions

  • Drugplacebo administration

    Also known as: isotonic saline serum intravenous administration

  • Drugmidazolam intravenous administration

    Also known as: hypnovel

06

What researchers measure

Primary outcomes

  1. visual analog scale of anxiety

    visual scale rated from 0 to 10 to describe the intensity of anxiety simple and reproducible measurement for a short period

    Time frame: baseline, up to the end of support in recovery room

Secondary outcomes

  1. salivary cortisol level

    biologic measurement non-invasive, inexpensive and easy to perform. two determinations before and after premedication (at least 20 minutes)

    Time frame: baseline and at the entrance in operating room

  2. Global anxiety

    rated from 4 to 20 for global anxiety and from 2 to 10 for information request anxiety is high above 10 for women and 12 for men

    Time frame: baseline

  3. Patient's satisfaction

    rated from 1 for bad management to 5 for excellent management assessed at the output of the recovery room

    Time frame: at the end of the support in recovery room

  4. Intraoperative consumption of hypnotics and opioids

    Cumulative dose of hypnotics and opioids reduced to dose per kilogram

    Time frame: at anesthesia induction up to 10 minutes

  5. Comfort induction

    rated from 1 for deep discomfort to 5 for good comfort

    Time frame: at anesthesia induction

  6. Intubation score

    Rated from 1 bed conditions for intubation to 5 for excellent conditions

    Time frame: after intubation

  7. Adverse midazolam effects

    assessed by variations of arterial pressure, heart rate, respiratory rate, oxygen saturation and end tidal of carbon dioxide for hemodynamics and respiratory adverse effects assessed by Observer's assessment of alertness/sedation for deep of sedation rated from 1 sleeping patient to 5 for awake patient

    Time frame: baseline up to the end of support in recovery room

  8. Output score of recovery room (Aldrete score)

    rated from 0 to 10 essential for the output of recovery room

    Time frame: at the end of support in recovery room

07

Study locations

1 site
  • Emergency, University Hopital
    Lille, 59000, France
08

References and documents

Publications

  • Sun GC, Hsu MC, Chia YY, Chen PY, Shaw FZ. Effects of age and gender on intravenous midazolam premedication: a randomized double-blind study. Br J Anaesth. 2008 Nov;101(5):632-9. doi: 10.1093/bja/aen251. Epub 2008 Sep 4. PubMed 18772216 ↗
  • Vogelsang J. The Visual Analog Scale: an accurate and sensitive method for self-reporting preoperative anxiety. J Post Anesth Nurs. 1988 Aug;3(4):235-9. No abstract available. PubMed 2457102 ↗
  • Bauer KP, Dom PM, Ramirez AM, O'Flaherty JE. Preoperative intravenous midazolam: benefits beyond anxiolysis. J Clin Anesth. 2004 May;16(3):177-83. doi: 10.1016/j.jclinane.2003.07.003. PubMed 15217656 ↗
  • Jerjes W, Jerjes WK, Swinson B, Kumar S, Leeson R, Wood PJ, Kattan M, Hopper C. Midazolam in the reduction of surgical stress: a randomized clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Nov;100(5):564-70. doi: 10.1016/j.tripleo.2005.02.087. PubMed 16243241 ↗
  • Wattier JM, Barreau O, Devos P, Prevost S, Vallet B, Lebuffe G. [Measure of preoperative anxiety and need for information with six issues]. Ann Fr Anesth Reanim. 2011 Jul-Aug;30(7-8):533-7. doi: 10.1016/j.annfar.2011.03.010. Epub 2011 May 23. French. PubMed 21602018 ↗
  • Moerman N, van Dam FS, Muller MJ, Oosting H. The Amsterdam Preoperative Anxiety and Information Scale (APAIS). Anesth Analg. 1996 Mar;82(3):445-51. doi: 10.1097/00000539-199603000-00002. PubMed 8623940 ↗
  • Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology. 1985 Mar;62(3):310-24. PubMed 3156545 ↗
  • Zalunardo MP, Ivleva-Sauerborn A, Seifert B, Spahn DR. [Quality of premedication and patient satisfaction after premedication with midazolam, clonidine or placebo : Randomized double-blind study with age-adjusted dosage]. Anaesthesist. 2010 May;59(5):410-8. doi: 10.1007/s00101-010-1695-9. German. PubMed 20224951 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02213302
Lead sponsor
University Hospital, Lille
Responsible party
Sponsor
First posted
Aug 11, 2014
Start date
Jul 2014
Primary completion
Jan 2016
Completion
Jan 2016
Last update
Feb 11, 2016

Study contacts

Elise Blondé-Zoonekynd, Physician
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion